Fluorescent in-situ hybridization (FISH) for BCR/ABL in chronic myeloid leukemia after bone marrow transplantation

Chauffaille, Maria de Lourdes Lopes Ferrari; Oliveira, José Salvador Rodrigues de; Romeo, Maura; Kerbauy, J

doi:10.1590/s1516-31802001000100005

Cited by 3 publications

(3 citation statements)

References 6 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The only data that we found were of Chauffaille et al (2001). They observed a 83% CCR rate one year after HSCT using FISH, but they used a double-color and single-fusion probe.…”

Section: Discussionmentioning

confidence: 79%

Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH

Vendrame-Goloni¹,

Carvalho-Salles²,

Ruiz³

et al. 2008

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for followup of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.

show abstract

“…The only data that we found were of Chauffaille et al (2001). They observed a 83% CCR rate one year after HSCT using FISH, but they used a double-color and single-fusion probe.…”

Section: Discussionmentioning

confidence: 79%

Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH

Vendrame-Goloni¹,

Carvalho-Salles²,

Ruiz³

et al. 2008

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Essa técnica pode ser usada para detectar o rearranjo BCR/ABL, ao diagnóstico, e tem sido preconizada para as situações em que não se tem metáfases para análise ou de Ph-mascarado no cariótipo. 24,25 Pela rapidez do teste, pode também ser usada em situações específicas.…”

Section: Citogenética Molecular: Hibridação In Situ Por Fluorescênciaunclassified

Análise citogenética e FISH no monitoramento da LMC em tratamento com inibidores da tirosino quinase

Chauffaille¹

2008

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

Análise citogenética e FISH no monitoramento da LMC em tratamento com inibidores da tirosino quinase Cytogenetics and FISH monitoring CML during tyrosine kinase inhibitors treatment Maria de Lourdes L. F. Chauffaille O monitoramento de tratamento com inibidor da tirosinoquinase (TK) tem sido feito com os objetivos de avaliar o sucesso da terapia e de definircondutas específicas nos casos nos quais não se obtem a remissão da LMC; naqueles em que ocorre a perda da remissão previamente alcançada, na eventualidade ou não de suspensão da medicação; quando há a evolução clonal a despeito da terapia ou o aparecimento de alterações clonais nas células Philadelphia (Ph)-negativas. Recomenda-se a avaliação citogenética aos três ou seis meses de instituição da terapêutica e, a partir daí, a cada seis meses até a remissão citogenética completa. Uma vez alcançada a remissão citogenética, o monitoramento passa a ser porPCR quantitativo em tempo real (PCR em tempo real, porém o cariótipo deve ser realizado a cada ano para a detecção de perda de resposta, alterações clonais em células Ph-negativas ou evolução clonal. Com efeito, só o cariótipo pode monitorar a aquisição de alteração clonal associada à progressão da doença. No presente manuscrito são também discutidos: Ph-variantes, deleção no derivado 9q e aparecimento de alterações clonais nas células Ph-negativas, situações menos freqüentes, mas que merecem monitoração mais amiúde. Rev. bras.

show abstract

“…These DNA probes contain a label (fluorescence) that allows their detection after hybridization to the target of interest. 3 Using FISH probes, very interesting data about CML have been demonstrated. The first generation of FISH probes (single fusion) was manufactured in order to show a signal for ABL gene (for example, a red dot -digoxigenin) and a signal in a different color for BCR gene (for example, a green dot -FITC).…”

Section: Molecular-cytogenetic Variant In Chronic Myeloid Leukemia Vamentioning

confidence: 99%

Molecular-cytogenetic variant in chronic myeloid leukemia

Chauffaille¹

2003

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

Fluorescent in-situ hybridization (FISH) for BCR/ABL in chronic myeloid leukemia after bone marrow transplantation

Abstract: The applicability of FISH is clear, particularly for residual disease detection. Classical and molecular cytogenetics are complementary methods.

Cited by 3 publications

References 6 publications

Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH

Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH

Análise citogenética e FISH no monitoramento da LMC em tratamento com inibidores da tirosino quinase

Molecular-cytogenetic variant in chronic myeloid leukemia

Contact Info

Product

Resources

About